Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 230

1.

Number Needed-to-Treat (NNT): Is it a necessary marker of therapeutic efficiency?

Monnier L, Colette C, Bonnet F, Owens D.

Diabetes Metab. 2020 Feb 5. pii: S1262-3636(20)30023-9. doi: 10.1016/j.diabet.2020.01.004. [Epub ahead of print] No abstract available.

PMID:
32035226
2.

Respective Contributions of Glycemic Variability and Mean Daily Glucose as Predictors of Hypoglycemia in Type 1 Diabetes: Are They Equivalent?

Monnier L, Wojtusciszyn A, Molinari N, Colette C, Renard E, Owens D.

Diabetes Care. 2020 Jan 27. pii: dc191549. doi: 10.2337/dc19-1549. [Epub ahead of print]

PMID:
31988062
3.

Calibration free continuous glucose monitoring (CGM) devices: Weighing up the benefits and limitations.

Monnier L, Colette C, Owens D.

Diabetes Metab. 2019 Sep 11:101118. doi: 10.1016/j.diabet.2019.101118. [Epub ahead of print] No abstract available.

PMID:
31520684
4.
5.

Glucocentric risk factors for macrovascular complications in diabetes: Glucose 'legacy' and 'variability'-what we see, know and try to comprehend.

Monnier L, Colette C, Schlienger JL, Bauduceau B, R Owens D.

Diabetes Metab. 2019 Oct;45(5):401-408. doi: 10.1016/j.diabet.2019.01.007. Epub 2019 Jan 24. Review.

PMID:
30685425
6.

The application of simple metrics in the assessment of glycaemic variability.

Monnier L, Colette C, Owens DR.

Diabetes Metab. 2018 Sep;44(4):313-319. doi: 10.1016/j.diabet.2018.02.008. Epub 2018 Mar 6. Review.

PMID:
29602622
7.

Pharmacological variability of insulins degludec and glargine 300U/mL: Equivalent or not?

Monnier L, Colette C.

Diabetes Metab. 2018 Feb;44(1):1-3. doi: 10.1016/j.diabet.2017.11.001. Epub 2017 Nov 14. No abstract available.

PMID:
29196025
8.

Glucose variability: Do we have to revisit the profusion of definitions to avoid confusion?

Monnier L, Colette C, Owens D.

Diabetes Metab. 2018 Mar;44(2):97-100. doi: 10.1016/j.diabet.2017.10.005. Epub 2017 Nov 16. No abstract available.

PMID:
29153486
9.

Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes.

Monnier L, Colette C, Wojtusciszyn A, Dejager S, Renard E, Molinari N, Owens DR.

Diabetes Care. 2017 Jul;40(7):832-838. doi: 10.2337/dc16-1769. Epub 2016 Dec 30.

PMID:
28039172
11.

Tailoring nutrient sequence and content to improve glucose tolerance: Why and how to do it.

Monnier L, Bonnet F, Colette C.

Diabetes Metab. 2016 Sep;42(4):211-4. doi: 10.1016/j.diabet.2016.04.003. Epub 2016 May 13. No abstract available.

PMID:
27184768
12.

Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy.

Monnier L, Colette C, Dejager S, Owens DR.

Rev Endocr Metab Disord. 2016 Mar;17(1):91-101. doi: 10.1007/s11154-016-9325-8. Review.

PMID:
26803295
13.

Postprandial and basal hyperglycaemia in type 2 diabetes: Contributions to overall glucose exposure and diabetic complications.

Monnier L, Colette C.

Diabetes Metab. 2015 Dec;41(6 Suppl 1):6S9-6S15. doi: 10.1016/S1262-3636(16)30003-9.

PMID:
26774019
14.

Ramadan and diabetes: What we see, learn and understand from continuous glucose monitoring.

Monnier L, El Azrak A, Lessan N, Rochd D, Colette C, Bonnet F.

Diabetes Metab. 2015 Dec;41(6):456-62. doi: 10.1016/j.diabet.2015.09.002. Epub 2015 Oct 23. Review.

PMID:
26476619
15.

Association of HbA1c variability with atherosclerosis in diabetes: simple marker, risk factor or statistical bias?

Monnier L, Colette C.

J Diabetes Complications. 2015 Aug;29(6):745-6. doi: 10.1016/j.jdiacomp.2015.05.002. Epub 2015 May 7. No abstract available.

PMID:
26082425
16.

Using the respective contributions of postprandial and basal glucose for tailoring treatments in type 2 diabetes.

Monnier L, Colette C.

Diabetes Metab. 2015 Jun;41(3):179-82. doi: 10.1016/j.diabet.2015.03.004. Epub 2015 Apr 17. No abstract available.

PMID:
25900889
17.

"Mild dysglycemia" in type 2 diabetes: to be neglected or not?

Monnier L, Colette C, Dejager S, Owens DR.

J Diabetes Complications. 2015 Apr;29(3):451-8. doi: 10.1016/j.jdiacomp.2014.12.004. Epub 2014 Dec 12. Review.

PMID:
25572605
18.

New insights on glucose homoeostasis during Ramadan.

Monnier L, Bonnet F, Colette C.

Diabetes Metab. 2015 Feb;41(1):1-4. doi: 10.1016/j.diabet.2014.11.005. Epub 2014 Dec 15. No abstract available.

PMID:
25523359
20.

The dawn phenomenon in type 2 diabetes: how to assess it in clinical practice?

Monnier L, Colette C, Dejager S, Owens D.

Diabetes Metab. 2015 Apr;41(2):132-7. doi: 10.1016/j.diabet.2014.10.002. Epub 2014 Nov 6.

PMID:
25457475
21.

Response to comment on Monnier et al. Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern? Diabetes Care 2013;36:4057-4062.

Monnier L, Colette C, Dejager S, Owens D.

Diabetes Care. 2014 Jul;37(7):e163. doi: 10.2337/dc14-0609. No abstract available.

PMID:
24963117
22.

Glycaemic variability and ambient hyperglycaemia: how and when are they linked?

Monnier L, Colette C.

Diabetes Metab. 2014 Sep;40(4):237-40. doi: 10.1016/j.diabet.2014.04.003. Epub 2014 May 19. No abstract available.

PMID:
24852510
23.

Residual dysglycemia when at target HbA(1c) of 7% (53mmol/mol) in persons with type 2 diabetes.

Monnier L, Colette C, Dejager S, Owens D.

Diabetes Res Clin Pract. 2014 Jun;104(3):370-5. doi: 10.1016/j.diabres.2014.03.012. Epub 2014 Mar 28.

PMID:
24735710
24.

Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern?

Monnier L, Colette C, Dejager S, Owens D.

Diabetes Care. 2013 Dec;36(12):4057-62. doi: 10.2337/dc12-2127. Epub 2013 Oct 29.

25.

Basal insulin analogs: from pathophysiology to therapy. What we see, know, and try to comprehend?

Monnier L, Colette C, Owens D.

Diabetes Metab. 2013 Dec;39(6):468-76. doi: 10.1016/j.diabet.2013.09.003. Epub 2013 Oct 17. Review.

PMID:
24139826
26.

Insulin and atherosclerosis: how are they related?

Monnier L, Hanefeld M, Schnell O, Colette C, Owens D.

Diabetes Metab. 2013 Apr;39(2):111-7. doi: 10.1016/j.diabet.2013.02.001. Epub 2013 Mar 15. Review.

PMID:
23507269
27.

Frequency and severity of the dawn phenomenon in type 2 diabetes: relationship to age.

Monnier L, Colette C, Sardinoux M, Baptista G, Regnier-Zerbib A, Owens D.

Diabetes Care. 2012 Dec;35(12):2597-9. doi: 10.2337/dc12-0385. Epub 2012 Sep 18.

28.

Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.

Guerci B, Monnier L, Serusclat P, Petit C, Valensi P, Huet D, Raccah D, Colette C, Quéré S, Dejager S.

Diabetes Metab. 2012 Oct;38(4):359-66. doi: 10.1016/j.diabet.2012.06.001. Epub 2012 Jul 17.

PMID:
22809630
29.

Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose?

Monnier L, Colette C, Comenducci A, Vallée D, Dejager S.

Diabetes Technol Ther. 2012 Oct;14(10):943-50. Epub 2012 Jul 9.

PMID:
22775317
30.

The glycemic triumvirate and diabetic complications: is the whole greater than the sum of its component parts?

Monnier L, Colette C, Owens D.

Diabetes Res Clin Pract. 2012 Mar;95(3):303-11. doi: 10.1016/j.diabres.2011.10.014. Epub 2011 Nov 5. Review.

PMID:
22056719
31.

Postprandial and basal glucose in type 2 diabetes: assessment and respective impacts.

Monnier L, Colette C, Owens D.

Diabetes Technol Ther. 2011 Jun;13 Suppl 1:S25-32. doi: 10.1089/dia.2010.0239. Review.

PMID:
21668334
32.

The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes.

Monnier L, Wojtusciszyn A, Colette C, Owens D.

Diabetes Technol Ther. 2011 Aug;13(8):813-8. doi: 10.1089/dia.2011.0049. Epub 2011 May 11.

PMID:
21561372
33.

Glycemic variability: can we bridge the divide between controversies?

Monnier L, Colette C.

Diabetes Care. 2011 Apr;34(4):1058-9. doi: 10.2337/dc11-0071. No abstract available.

34.

Insulin therapy has a complex relationship with measure of oxidative stress in type 2 diabetes: a case for further study.

Monnier L, Colette C, Michel F, Cristol JP, Owens DR.

Diabetes Metab Res Rev. 2011 May;27(4):348-53. doi: 10.1002/dmrr.1174.

PMID:
21309055
35.

Vitamin D and diabetes: much ado about nothing?

Monnier L, Colette C.

Diabetes Metab. 2010 Nov;36(5):323-5. doi: 10.1016/j.diabet.2010.06.003. Epub 2010 Aug 4. No abstract available.

PMID:
20688551
36.

Target for glycemic control: concentrating on glucose.

Monnier L, Colette C.

Diabetes Care. 2009 Nov;32 Suppl 2:S199-204. doi: 10.2337/dc09-S310. Review. No abstract available.

37.

Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy.

Monnier L, Colette C, Mas E, Michel F, Cristol JP, Boegner C, Owens DR.

Diabetologia. 2010 Mar;53(3):562-71. doi: 10.1007/s00125-009-1574-6. Epub 2009 Nov 5.

PMID:
19890623
38.

Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it?

Monnier L, Colette C, Owens DR.

J Diabetes Sci Technol. 2008 Nov;2(6):1094-100.

39.

Diabetes: The HEART2D trial--new questions beyond answers.

Monnier L, Colette C.

Nat Rev Endocrinol. 2009 Jun;5(6):299-300. doi: 10.1038/nrendo.2009.98. No abstract available.

PMID:
19465895
40.

Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept.

Monnier L, Colette C, Owens DR.

Diabetes Metab Res Rev. 2009 Jul;25(5):393-402. doi: 10.1002/dmrr.962. Review.

PMID:
19437415
41.

Fasting glucose and postprandial glycemia: which is the best target for improving outcomes? The Apollo and 4-T Trials.

Monnier L, Colette C.

Expert Opin Pharmacother. 2008 Nov;9(16):2857-65. doi: 10.1517/14656566.9.16.2857 . Review.

PMID:
18937617
42.

Targeting prandial hyperglycemia: how important is it and how best to do this?

Monnier L, Colette C.

Curr Diab Rep. 2008 Oct;8(5):368-74.

PMID:
18778585
43.

Type 2 diabetes: a well-characterised but suboptimally controlled disease. Can we bridge the divide?

Monnier L, Colette C, Owens DR.

Diabetes Metab. 2008 Jun;34(3):207-16. doi: 10.1016/j.diabet.2008.01.011. Epub 2008 Jun 3. Review.

PMID:
18511324
44.

Glycemic variability: should we and can we prevent it?

Monnier L, Colette C.

Diabetes Care. 2008 Feb;31 Suppl 2:S150-4. doi: 10.2337/dc08-s241.

PMID:
18227477
45.
46.

Contribution of postprandial glucose to chronic hyperglycaemia: from the "glucose triad" to the trilogy of "sevens".

Monnier L, Colette C, Boniface H.

Diabetes Metab. 2006 Sep;32 Spec No2:2S11-6. Review.

PMID:
17375401
47.

Continuous glucose monitoring in patients with type 2 diabetes: Why? When? Whom?

Monnier L, Colette C, Boegner C, Pham TC, Lapinski H, Boniface H.

Diabetes Metab. 2007 Sep;33(4):247-52. Epub 2007 Feb 21. Review.

PMID:
17320449
48.

The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes.

Monnier L, Colette C, Dunseath GJ, Owens DR.

Diabetes Care. 2007 Feb;30(2):263-9.

PMID:
17259492
49.

The effect of glucose variability on the risk of microvascular complications in type 1 diabetes.

Monnier L, Colette C, Leiter L, Ceriello A, Hanefeld M, Owens D, Tajima N, Tuomiletho J, Davidson J; PGR Group.

Diabetes Care. 2007 Jan;30(1):185-6; author reply 187-8. No abstract available.

PMID:
17192363
50.

Contributions of fasting and postprandial glucose to hemoglobin A1c.

Monnier L, Colette C.

Endocr Pract. 2006 Jan-Feb;12 Suppl 1:42-6. Review.

PMID:
16627379

Supplemental Content

Loading ...
Support Center